Further to your point @johndprent that market share of anthracyclines might increase due to efficacy & safety, a reminder from the researchers that "another potential key feature of Zantrene is its ability to allow patients to continue anthracycline-based treatment beyond the maximum lifetime cumulative dose", ie existing patients can continue to use the anthracycline instead of stopping treatment.
The pharma's will love this too !
Ann: Race releases cardioprotection market potential data, page-82
-
- There are more pages in this discussion • 159 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
0.010(0.64%) |
Mkt cap ! $267.5M | |||
| Open | High | Low | Value | Volume |
| $1.58 | $1.64 | $1.55 | $134.0K | 84.34K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6283 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.60 | 6559 | 2 |
View Market Depth
| Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |